SCHEMBL17243629

SCHEMBL17243629

O=C(Nc1c(Cl)cncc1Cl)c1nn(-c2cccc(Oc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 10/20 0.46
KCNH2 Q12809 7/20 0.46
PDE4B Q07343 4/20 0.38
PDE4C Q08493 4/20 0.38
PDE4D Q08499 4/20 0.38
CYP2C9 P11712 1/20 0.38
RARG P13631 1/20 0.35
RORC P51449 1/20 0.35
FNTA P49354 2/20 0.34
FNTB P49356 2/20 0.34
PKD1 P98161 1/20 0.33
MAP3K14 Q99558 1/20 0.33
MET P08581 2/20 0.32
RIPK1 Q13546 2/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17243627 0.88 PDE4A (0.49) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243636 0.87 PDE4A (0.46) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243925 0.87 KCNH2 (0.52) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243634 0.87 PDE4A (0.45) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243631 0.87 PDE4A (0.45) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243619 0.82 PDE4B (0.54) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243635 0.79 PDE4A (0.48) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243633 0.79 PDE4A (0.48) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243924 0.79 PDE4A (0.45) PDE4AKCNH2PDE4BPDE4CPDE4D
SCHEMBL17243626 0.78 KCNH2 (0.51) PDE4AKCNH2PDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181244-B1 Substituted pyrido[2,3-c]pyridazin-4(1H)-ones as tumor necrosis factor alpha and phosphodiesterase 4 inhibitors Xuanzhu Pharma Co., Ltd. (CN) 2015-11-10 US disclosed